Document Type
Journal Article
Publication Date
7-30-2014
Journal
PLoS ONE
Volume
9
Issue
7
Inclusive Pages
Article number e103285
DOI
10.1371/journal.pone.0103285
Keywords
Coinfection; HIV Infections/urine; Lipopolysaccharides/urine; Tuberculosis--diagnosis; Tuberculosis--urine
Abstract
Background
Detection of the mycobacterial cell wall antigen lipoarabinomannan (LAM) in urine can be used to diagnose HIV-associated tuberculosis (TB) using a qualitative (positive/negative) read-out. However, it is not known whether the quantity of LAM present in urine provides additional prognostic information.
Methods/Findings
Consecutively recruited adult outpatients initiating antiretroviral therapy (ART) in South Africa were investigated for TB regardless of clinical symptoms using sputum smear microscopy and liquid culture (reference standard). Urine samples were tested using the Clearview TB-ELISA for LAM and the Xpert MTB/RIF assay. The ELISA optical densities (OD) were used as a quantitative assessment of urine LAM. Among 514 patients with complete sputum and urine LAM OD results, culture-confirmed TB was diagnosed in 84 patients. Twenty-three (27.3%) were LAM-positive with a median LAM OD of 0.68 (IQR 0.16–2.43; range, 0.10–3.29) and 61 (72.6%) were LAM negative (LAM OD
Conclusions
In patients with HIV-associated TB, concentrations of LAM in urine were strongly associated with a range of poor prognostic characteristics known to be associated with mortality risk. Urine LAM assays with a semi-quantitative (negative vs. low-positive vs. high-positive) read-out may have improved clinical utility over assays with a simple binary result.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
APA Citation
Kerkhoff, A.D., Wood, R., Vogt, M., Lawn, S.D. (2014) Prognostic Value of a Quantitative Analysis of Lipoarabinomannan in Urine from Patients with HIV-Associated Tuberculosis. PLoS ONE 9(7): e103285. DOI: 10.1371/journal.pone.0103285.
Peer Reviewed
1
Open Access
1
Comments
Reproduced with permission of PLoS ONE.